Merrimack Pharmaceuticals, Inc. (MACK)
| Market Cap | 90.32M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | 1.34M |
| Shares Out | 13.38M |
| EPS (ttm) | 0.10 |
| PE Ratio | 65.20 |
| Forward PE | n/a |
| Dividend | $1.50 |
| Dividend Yield | 22.96% |
| Trading Day | March 8 |
| Last Price | $6.52 |
| Previous Close | $6.57 |
| Change ($) | -0.05 |
| Change (%) | -0.76% |
| Day's Open | 6.73 |
| Day's Range | 6.44 - 6.80 |
| Day's Volume | 53,696 |
| 52-Week Range | 1.49 - 9.45 |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals Q3 2020 Earnings Release
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Reports Second Quarter 2020 Financial Results
Merrimack Pharmaceuticals: SCLC Presents A Lower Hurdle For Approval Than Initially Assumed
Merrimack Pharmaceuticals - A Better Way To Invest In Biotechnology
Merrimack Pharmaceuticals is a special-situations investment.
Merrimack Pharmaceuticals Inc. has announced that it will be discontinuing one of its cancer drugs, as well as conducting layoffs.
About MACK
Merrimack Pharmaceuticals operates as a biopharmaceutical company. The company was incorporated in 1993 and is based in Cambridge, Massachusetts.
| Industry Biotechnology | IPO Date Mar 29, 2012 |
| CEO Gary L. Crocker M.B.A., MBA | |
| Stock Exchange NASDAQ | Ticker Symbol MACK |
Analyst Forecasts
The average 12-month stock price forecast for MACK is 4.00, which is a decrease of -38.65% from the latest price.